Roche to acquire BioImagene

BASEL, Switzerland Swiss drug maker Roche will acquire a U.S. diagnostics company that develops technology used to create images of patients’ tissue samples.

Roche announced that it would acquire all of Sunnyvale, Calif.-based BioImagene for $100 million. BioImagene works in the field of digital pathology, a technology that allows the capturing, management and analysis of images of patients’ tissue samples, creating high-resolution images from glass microscope slides.

In other news, according to The New York Times, Roche is buying Cambridge, Mass.-based Aileron Therapeutics for $25 million and up to $1.1 billion in milestone payments. Aileron is the developer of stapled peptide technology, which involves delivering medicine inside of cells and could yield treatments for diseases such as cancer and autoimmune disorders.